Trial Profile
A Phase II Trial of Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer Who Have Failed at Least Two Prior Therapies.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Imatinib (Primary)
- Indications Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 22 Nov 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 04 Jul 2009 New trial record